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Identification of Drug Metabolites of Antidepressant Medications, Venlafaxine,
Escitalopram, and Duloxetine in Rat Liver Microsome Using Compact Mass
Spectrometry
Dani K. Schmaus and Dr. Myoung E. Lee
Department of Chemistry, Winona State University, Winona, Minnesota

ABSTRACT

Antidepressants are commonly used for depression and anxiety. It is known that most
drugs are metabolized by enzymes within the liver. The enzymes metabolize drugs by
altering them to become more polar so that they can be excreted through the urine or
bile. As a future pharmacist, I want to know how antidepressants are altered within
the body before I distribute them. This study was done to determine the outcome of
metabolism within three different antidepressants: venlafaxine (Effexor), duloxetine
(Cymbalta) and escitalopram (Lexapro). These three drugs were mixed with rat liver
microsomes and NADPH-generating system in phosphate buffer at pH 7.4. All samples
were incubated for two hours at 37C. Each sample was subjected to the compact mass
spectrometer fitted with a C18 reverse phase column. The results indicated that all
three drugs underwent N-demethylation but not aromatic hydroxylation during
metabolism. When looking at the area of the peaks within each metabolized drug,
duloxetine metabolized the most out of all three drugs. Up to 30-70% of duloxetine
was metabolized. Several controls were also incubated and analyzed, such as the
mixture without the drug, the mixture without NADPH-generating system, the mixture
without the rat liver microsome and a mixture of just the drug and buffer. Some of the
controls without the drug or the microsome still showed MS peaks with the same
molecular weight as the drugs or the metabolites. These peaks could indicate that
there are contaminants within the solvent or the phosphate buffer that have similar
molecular weights. The future goal is to repeat these experiments using HPLC/CMS to
further separate the metabolites. Using different drugs would also explain the
outcome of metabolism a little further, such as if a drug can be both demethylated and
hydroxylated.

DISCUSSION

MATERIALS AND METHODS

CONCLUSION

Venlafaxine, escitalopram, duloxetine, NADP, Glucose-6-Phosphate, and Glucose-6-Phosphate
Dehydrogenase and rat liver microsome were purchased from Sigma Aldrich. Luna C18 reverse phase
column (3 micrometer, 50 mm x 2 mm) was purchased from Phenomenex. Each drug’s samples were
metabolized and evaluated using an Advion Expression S Compact Mass Spectrometer equipped with an
electrospray ionizer (ESI) and a Phenomenex Luna C18 column. The running time was 15 minutes per sample
with a mobile phase of 95:5 acetonitrile:water and 2 mM ammonium acetate with a 0.2 mL/min flow rate.
The injection volume was 5 𝜇𝜇L. Three different concentrations of each drug were used along with four
different controls. The drug concentrations were 100, 250, and 800 𝜇𝜇𝑀𝑀. For each drug, 65 𝜇𝜇L of these
concentrations along with a mixture of 35 μL NADPH-generating system and 25 𝜇𝜇L microsomal suspension in
50 mM potassium phosphate buffer at pH 7.4 were added. The final concentration of NADP, glucose-6phosphate, glucose-6-phosphate dehydrogenase, and microsome were 1 mM, 5 mM, 0.5 U, and 0.2 mg/mL,
respectively. The four controls had the following composition: (1) drug only, (2) drug with the microsome but
without NADPH-generating system, (3) drug with NADPH-generating system only, and (4) NADPH-generating
system and microsome without the drug. Samples were then incubated at 37oC for a period of 2 hours and
then 250 𝜇𝜇L methanol was added to stop the reaction. These samples were then centrifuged so that
the supernatant could be taken and diluted to 1/20 (venlafaxine and escitalopram) or 1/100 (duloxetine) in
the mobile phase before injecting the samples within the mass spectrometer. All injections within the mass
spectrometer were performed in triplicates to ensure equal conditions for data collection and calculations.

According to the results, escitalopram, duloxetine and venlafaxine all
underwent N-demethylation but not aromatic hydroxylation during
metabolism in rat liver microsome. Even though duloxetine was only Ndemethylated, it metabolized the most out of all three drugs up to 30-70%. In
conclusion, it was confirmed that escitalopram, venlafaxine and duloxetine
needed rat liver microsomes in order to metabolize. However, it was also
confirmed that only escitalopram and venlafaxine needed NADPH-generating
system as well, in order to metabolize. In further studies, repeating these
experiments using HPLC/CMS techniques to further separate the metabolites
would be ideal. Although duloxetine metabolized the most, it would be easier
to understand how or why it metabolized the most if we were able to separate
the metabolites further by using these techniques. Using different drugs would
also explain the outcome of metabolism a little further.

RESULTS

Escitalopram

INTRODUCTION
Depression is a serious mental illness that many college students experience. Between
deadlines and relationships, college can be a very challenging time, making students feel very
dispirited. It is hard to return from that feeling of anguish, so many students turn to
antidepressant medications to feel better again. Duloxetine (Cymbalta), escitalopram
(Lexapro) and venlafaxine (Effexor) are all antidepressant medications that inhibit serotoninnorepinephrine reuptake within the brain (Lam et al.). There are multiple dosages that can be
prescribed, all based on severity of the depression. A blood cell count, test on hormone levels
and a metabolic panel of the liver is also taken to decide the dosage for a patient. Cytochrome
P450 (CYP) are enzymes of the liver that metabolize things that a person may ingest, including
antidepressant medications. There are multiple different enzymes within the liver, all working
together, but completing different steps in the metabolism process. CYP1A2, CYP2C19 and
CYP2D6 are three of the multiple enzymes used within the liver. It isn’t fully known how much
of each enzyme is used within the liver, but it is known that each would be poor metabolizers
if they had to work alone. Their greatest substrates are antidepressant drugs, including
venlafaxine, escitalopram and duloxetine. As a college student that is surrounded by so many
students in a low-mood, I feel it is necessary to determine how these enzymes in the liver
metabolize the antidepressant medications given and to know that the reaction does not
result in toxins being produced in the body. Also, as a pharmacy technician, I dispense
antidepressants almost daily. Therefore, I’m very interested in knowing the details of how the
liver metabolizes these medications.
Venlafaxine is a medication specifically to treat symptoms of low-mood, or depression,
whereas duloxetine and escitalopram are to treat symptoms of low-mood and anxiety.
However, duloxetine is also used to treat long-term pain from nerve diseases and diabetic
nerve problems, as well as fibromyalgia. It has been discovered that the substrates for CYP2D6
are both venlafaxine and duloxetine, with escitalopram and sertraline (another similar
antidepressant medication) as smaller substrates (Brachtendorf, et al.). CYP1A2 has been
discovered to specifically catalyze in the presence of escitalopram and duloxetine, as well as
somewhat in the presence of venlafaxine (Lobo, et al.). CYP2C19 is known for having the most
involvement in metabolizing antidepressant medications due to having three main substrates
and two other smaller substrates. The three main substrates are escitalopram, duloxetine and
amitriptyline (another similar antidepressant medication) and the three partial substrates are
venlafaxine and sertraline (Zhan, et al.).
My proposal is to investigate how rat liver microsomes, which contain many CYP enzymes,
react with each of the three medications, venlafaxine, escitalopram and duloxetine. The
metabolism of each antidepressant medication highly depends on whether or not the
cytochrome catalyzes a reaction, making the drug soluble. But what is this reaction? And are
these man-made medications safe for our bodies after these reactions occur? By developing
an assay to perform to help further the reaction and determine its affinity, I will find which of
these drug metabolizes the most efficiently. By viewing the breakdown of the drugs with and
without microsomes, I will determine how each drug is metabolized within the body.

Figure 3: MS Chromatogram of Aromatic Hydroxylation of
Escitalopram

Figure 1: MS Chromatogram of N-Demethylation of Escitalopram
This figure shows three trials with their retention time and area at the
molecular weight of 311.2 with the concentration of 800 𝜇𝜇𝑀𝑀. This is the
molecular weight of escitalopram (325) with a methyl group subtracted
from it (-14). Each sample was injected into the mass spectrometer
three times in about a 1.5-minute interval. The demethylated
metabolite shows up at 0.59 min, 2.18 min, and 3.81 min. These peaks
were not visible without the presence of NADPH-generating system,
meaning that escitalopram depends on this to metabolize.

This figure shows three trials with their retention time and area at
the molecular weight of 343.2 with the concentration of 800 𝜇𝜇𝜇𝜇.
This is the molecular weight of escitalopram (325) with a water
group added to it (+18). Each sample was injected into the mass
spectrometer three times in about a 1.5-minute interval. The
metabolite does not show up at all. The peaks shown above have
retention times that are later than the retention time of the drug at
the molecular weight of 325, indicating that there is no
hydroxylated metabolite.

Figure 2: N-Demethylation of Escitalopram
This figure shows the average of all three trials (Figure 1)
plotted against their concentrations: 0, 100, 250 and 800 𝜇𝜇𝜇𝜇.
This plot resembles a hyperbolic curve.1-3% of the original
concentration was metabolized.

Figure 5: MS Chromatogram of N-Demethylation of Venlafaxine

Figure 7: MS Chromatogram of Aromatic Hydroxylation of Venlafaxine

This figure shows three trials with their retention time and area at the
molecular weight of 264.2 with the concentration of 800 𝜇𝜇𝜇𝜇. This is the
molecular weight of venlafaxine (278) with a methyl group subtracted
from it (-14). Each sample was injected into the mass spectrometer
three times every four minutes. The demethylated metabolite shows up
at 1.37 min, 5.35 min, and 9.52 min. There were two peaks developed
per round of injections, which means that one of the peaks was not the
demethylated metabolite. Because the metabolite is known to show up
at a retention time before that of the drug’s (1.71 min, 5.69 min and
9.86 min), the first peak is the actual indication of demethylated
metabolites. These peaks were not visible without the presence of
NADPH-generating system. This means that venlafaxine is dependent on
this in order to metabolize.

This figure shows three trials with their retention time and area at the
molecular weight of 296.2 with the concentration of 800 𝜇𝜇𝜇𝜇. This is the
molecular weight of venlafaxine (278) with a water group added to it
(+18). Each sample was injected into the mass spectrometer three times
every four minutes. The hydroxylated metabolite shows up at 1.14 min,
5.14 min, and 9.29 min.

Figure 6: N-Demethylation of Venlafaxine
This figure shows the average of all three trials (Figure 5) plotted
against their concentrations: 0, 100, 250 and 800 𝜇𝜇𝜇𝜇. This plot
resembles a hyperbolic curve. 0.9-1.5% of the original
concentration was metabolized.

Venlafaxine
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This figure shows three trials with their retention time and area at
the molecular weight of 284.2 with the concentration of 800 𝜇𝜇𝜇𝜇.
This is the molecular weight of duloxetine (298) with a methyl group
subtracted from it (-14). Each sample was injected into the mass
spectrometer three times every four minutes. The demethylated
metabolite shows up at 0.65 min, 4.83 min, and 8.66 min. These
peaks were not visible without the presence of NADPH-generating
system, meaning that duloxetine is not dependent on it to
metabolize.

Escitalopram

This figure shows the average of all three trials (Figure 3)
plotted against their concentrations: 0, 100, 250 and 800
𝜇𝜇𝜇𝜇. This plot indicates no hydroxylation metabolites.

Venlafaxine

Figure 9: MS Chromatogram of N-Demethylation of Duloxetine

Duloxetine

Figure 4: Aromatic Hydroxylation of Escitalopram

Escitalopram was the first drug tested, containing seven samples, three of different concentrations known as
100, 250 and 800 𝜇𝜇𝑀𝑀 and four controls known as the mixture without the drug, the mixture without
NADPH-generating system, the mixture without the rat liver microsome and just the drug alone. For each
sample, the three peaks at escitalopram’s molecular weight plus one for the original drug, minus fourteen
(N-demethylation), and plus eighteen (aromatic hydroxylation) were selectively monitored and used to
determine its metabolites. At the molecular weight of 311.2, three strong peaks with retention times of 0.59
min, 2.18 min, and 3.81 min indicated N-demethylated metabolites at 800 𝜇𝜇𝜇𝜇. Escitalopram’s Ndemethylation metabolized between 1-3%. At the molecular weight of 343.2, three small peaks with
retention times of 0.76 min, 2.33 min, and 3.96 min that showed up later than the drug at a molecular
weight of 325.2 indicated that there are no aromatic hydroxylated metabolites at 800 𝜇𝜇𝜇𝜇. Even though
there is a small peak that forms before each peak that has the right retention times, it is still not thought to
be the metabolites because the peak only appears in the 800 𝜇𝜇𝜇𝜇 concentration and is not a clean peak. In
the 100 and 250 𝜇𝜇𝜇𝜇 concentrations, there are no peaks at the molecular weight of 343.2, there is only noise
on each chromatogram. It is unknown what the peak within the 800 𝜇𝜇𝜇𝜇 chromatogram is, but it could
possibly be another component of the sample with the same molecular weight. Further controls would need
to be studied to conclude which constituent contains the same molecular weight as the possible metabolite.
Venlafaxine was the second drug to be studied and interpreted by averaging the three peaks shown for each
of the seven samples. At the molecular weight of 264.2, two strong peaks per injection displayed. Between
the two of them, the first peak for each injection with retention times of 1.37 min, 5.35 min, and 9.52 min
indicated N-demethylated metabolites at 800 𝜇𝜇𝜇𝜇. The second peak for each injection with retention times
of 2.26 min, 6.23 min, and 10.40 min did not indicate N-demethylated metabolites due to the original drug
at the molecular weight of 278.2 having retention times happening earlier than the these peaks. Metabolites
must have retention times earlier than the drug’s in order to actually prove metabolism since the
metabolites are more polar than the original drug. Venlafaxine was N-demethylated between 0.9-1.5%. At
the molecular weight of 296.2, three peaks with retention times of 1.14 min, 5.14 min, and 9.29 min
indicated aromatic hydroxylated metabolites. However, when plotting the average of its peaks with each
concentration injected, the plot did not represent a hyperbolic curve. A hyperbolic curve indicates the
increase in the average area of the peak, eventually plateauing once it hits the saturation. Because the plot
did not represent a hyperbolic curve, it can be assumed that aromatic hydroxylation did not actually happen
within the metabolism of venlafaxine. It is unsure what these peaks are actually indicating that further
studies with more controls would need to be completed in order identify them. Duloxetine was the last drug
to be studied. At the molecular weight of 284.2, three strong peaks with the retention times of 0.65 min,
4.83 min, and 8.66 min indicated N-demethylated metabolites at 800 𝜇𝜇𝜇𝜇. Duloxetine’s N-demethylation
metabolized between 33-72%. At the molecular weight of 316.2, we did not detect strong peaks. Therefore,
it is indicated that there was not any aromatic hydroxylation at 800 𝜇𝜇𝜇𝜇. Out of the three drugs, duloxetine
metabolized more than escitalopram and venlafaxine. This is interesting and we are not sure why. When
referring to the structure of duloxetine compared escitalopram and venlafaxine, duloxetine contains a
secondary amine as opposed to tertiary amines of the other two drugs. Tertiary amines are known to be
demethylated about 3-4 times as rapidly as the secondary amine (Brodie and Gillette), therefore, testing of
another antidepressant containing a secondary amine would be necessary.
When analyzing the controls for each drug, the control that contained only the drug and microsome without
the NADPH-generating system gave interesting results. For escitalopram and venlafaxine, the metabolites did
not show up on the chromatogram in the absence of the NADPH-generating system. However, for
duloxetine, the metabolites of N-demethylation did show up on the chromatogram in the presence of
NADPH-generating system. This concludes that both escitalopram and venlafaxine need NADPH-generating
system when metabolizing and duloxetine does not. NADPH is required for N-demethylation, so we are
unsure why this is the case.
While injecting the samples of escitalopram into the compact mass spectrometer, each sample was injected
three times within 1.5 minute intervals for a total of five minutes. The syringe was changed per sample,
along with a wash of the needle and the column. After analyzing the data, it was then decided that in order
to see a better separation between the three injections that the intervals needed to be stretched to every
four minutes for a total of twelve minutes. In order to rely on retention times of the peaks appearing, it was
practiced to inject the sample at exactly four minutes every time. There were a couple of times that samples
were injected at a slightly later time, which could have affected the retention times slightly. Overall, this
experiment ran very smooth and gave useful results.

Figure 11: MS Chromatogram of Aromatic Hydroxylation of Duloxetine

Figure 10: N-Demethylation of Duloxetine
This figure shows the average of all three trials (Figure 9) plotted
against their concentrations: 0, 100, 250 and 800 𝜇𝜇𝜇𝜇. This plot
resembles a hyperbolic curve. 33-72% of the original concentration
was metabolized.

This figure shows three trials with their retention time and area at the
molecular weight of 316.2 with the concentration of 800 𝜇𝜇𝜇𝜇. This is the
molecular weight of duloxetine (298) with a water group added to it (+18).
Each sample was injected into the mass spectrometer three times every
four minutes. There are no strong peaks that would indicate hydroxylated
metabolites.

Figure 12: Aromatic Hydroxylation of Duloxetine
This figure shows the average of all three trials (Figure 11) plotted
against their concentrations: 0, 100, 250 and 800 𝜇𝜇𝜇𝜇. This plot
indicates no hydroxylation metabolites.
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Identification of Drug Metabolites of Antidepressant Medications, Venlafaxine, Escitalopram
and Duloxetine, in Rat Liver Microsome Using Compact Mass Spectrometry
Dani K. Schmaus and Dr. Myoung E. Lee
Department of Chemistry, Winona State University, Winona, Minnesota
Abstract:
Antidepressants are commonly used for depression and anxiety. It is known that most
drugs are metabolized by enzymes within the liver. The enzymes metabolize drugs by altering
them to become more polar so that they can be excreted through the urine or bile. As a future
pharmacist, I want to know how antidepressants are altered within the body before I distribute
them. This study was done to determine the outcome of metabolism within three different
antidepressants: venlafaxine (Effexor), duloxetine (Cymbalta) and escitalopram (Lexapro).
These three drugs were mixed with rat liver microsomes and NADPH-generating system in
phosphate buffer at pH 7.4. All samples were incubated for two hours at 37C. Each sample was
subjected to the compact mass spectrometer fitted with a C18 reverse phase column. The
results indicated that all three drugs underwent N-demethylation but not aromatic
hydroxylation during metabolism. When looking at the area of the peaks within each
metabolized drug, duloxetine metabolized the most out of all three drugs. Up to 30-70% of
duloxetine was metabolized. Several controls were also incubated and analyzed, such as the
mixture without the drug, the mixture without NADPH-generating system, the mixture without
the rat liver microsome and a mixture of just the drug and buffer. Some of the controls without
the drug or the microsome still showed MS peaks with the same molecular weight as the drugs
or the metabolites. These peaks could indicate that there are contaminants within the solvent
or the phosphate buffer that have similar molecular weights. The future goal is to repeat these
experiments using HPLC/CMS to further separate the metabolites. Using different drugs would
also explain the outcome of metabolism a little further, such as if a drug can be both
demethylated and hydroxylated.
Introduction:
Depression is a serious mental illness that many college students experience. Between
deadlines and relationships, college can be a very challenging time, making students feel very
dispirited. It is hard to return from that feeling of anguish, so many students turn to
antidepressant medications to feel better again. Duloxetine (Cymbalta), escitalopram (Lexapro)
and venlafaxine (Effexor) are all antidepressant medications that inhibit serotoninnorepinephrine reuptake within the brain (Lam et al.). There are multiple dosages that can be
prescribed, all based on severity of the depression. A blood cell count, test on hormone levels
and a metabolic panel of the liver is also taken to decide the dosage for a patient. Cytochrome
P450 (CYP) are enzymes of the liver that metabolize things that a person may ingest, including
antidepressant medications. There are multiple different enzymes within the liver, all working
together, but completing different steps in the metabolism process. CYP1A2, CYP2C19 and
CYP2D6 are three of the multiple enzymes used within the liver. It isn’t fully known how much
of each enzyme is used within the liver, but it is known that each would be poor metabolizers if
they had to work alone. Their greatest substrates are antidepressant drugs, including
venlafaxine, escitalopram and duloxetine. As a college student that is surrounded by so many

students in a low-mood, I feel it is necessary to determine how these enzymes in the liver
metabolize the antidepressant medications given and to know that the reaction does not result
in toxins being produced in the body. Also, as a pharmacy technician, I dispense
antidepressants almost daily. Therefore, I’m very interested in knowing the details of how the
liver metabolizes these medications.
Venlafaxine is a medication specifically to treat symptoms of low-mood, or depression, whereas
duloxetine and escitalopram are to treat symptoms of low-mood and anxiety. However,
duloxetine is also used to treat long-term pain from nerve diseases and diabetic nerve
problems, as well as fibromyalgia. It has been discovered that the substrates for CYP2D6 are
both venlafaxine and duloxetine, with escitalopram and sertraline (another similar
antidepressant medication) as smaller substrates (Brachtendorf, et al.). CYP1A2 has been
discovered to specifically catalyze in the presence of escitalopram and duloxetine, as well as
somewhat in the presence of venlafaxine (Lobo, et al.). CYP2C19 is known for having the most
involvement in metabolizing antidepressant medications due to having three main substrates
and two other smaller substrates. The three main substrates are escitalopram, duloxetine and
amitriptyline (another similar antidepressant medication) and the three partial substrates are
venlafaxine and sertraline (Zhan, et al.).
My proposal is to investigate how rat liver microsomes, which contain many CYP enzymes, react
with each of the three medications, venlafaxine, escitalopram and duloxetine. The metabolism
of each antidepressant medication highly depends on whether the cytochrome catalyzes a
reaction, making the drug soluble. But what is this reaction? And are these man-made
medications safe for our bodies after these reactions occur? By developing an assay to perform
to help further the reaction and determine its affinity, I will find which of these drugs
metabolizes the most efficiently. By viewing the breakdown of the drugs with and without
microsomes, I will determine how each drug is metabolized within the body.
Materials and Methods:
Venlafaxine, escitalopram, duloxetine, NADP, Glucose-6-Phosphate, and Glucose-6-Phosphate
Dehydrogenase and rat liver microsome were purchased from Sigma Aldrich. Luna C18 reverse
phase column (3 micrometer, 50 mm x 2 mm) was purchased from Phenomenex. Each drug’s
samples were metabolized and evaluated using Advion Expressions Compact Mass
Spectrometer fitted with an electrospray ionizer (ESI) and a Phenomenex Luna C18 column
running for 15 minutes per sample with a mobile phase of 95:5 acetonitrile:water 2 𝜇𝜇𝜇𝜇
ammonium acetate with a 0.2 mL/min flow rate. Three different concentrations of each drug
were used along with four different controls. Each of the drug concentrations were 100, 250
and 800 𝜇𝜇𝜇𝜇. For each drug, 65 𝜇𝜇L of these concentrations along with a mixture of 35 μL
NADPH-generating system and 25 𝜇𝜇L microsomal suspension in 50 𝜇𝜇𝜇𝜇 potassium phosphate
buffer at pH 7.4. The final concentration of NADP, glucose-6-phosphate, glucose-6-phosphate
dehydrogenase, and microsome were 1 𝜇𝜇𝜇𝜇, 5 𝜇𝜇𝜇𝜇, 0.5 U, and 0.2 mg/mL, respectively. The four
controls had the following composition: (1) drug only, (2) drug with the microsome only, (3)
drug with NADPH-generating system only, and (4) NADPH-generating system and microsome
without the drug. Samples were then incubated at 37 degrees C for a period of 2 hours and
then 250 𝜇𝜇𝜇𝜇 methanol was added to stop the reaction. These samples were then centrifuged
so that the supernatant could be taken and diluted to 1/20 (venlafaxine and escitalopram) or

1/100 (duloxetine) in the mobile phase before injecting the samples within the mass
spectrometer. All injections within the mass spectrometer were performed in triplicates to
ensure equal conditions for data collection and calculations.
Protocol for Venlafaxine:
1. Create NADPH-generating system by adding 0.492 mg of NADP in 50 𝜇𝜇𝜇𝜇 of buffer to
make 12.5 mM NADP, add 200 𝜇𝜇𝜇𝜇 of buffer into the 100 U vial of G6P dehydrogenase,
and remove 25 𝜇𝜇𝜇𝜇 of the solution to make 12.5 U of G6P dehydrogenase. Create G6P by
adding 0.88 mg of G6P in 100 𝜇𝜇𝜇𝜇 of buffer to make 31.2 mM G6P all together.
Measure out about 0.5 mg of NADP and about 1 mg G6P and add to vial with 160 𝜇𝜇𝜇𝜇 of
buffer. Mix well.
2. Create a stock of Venlafaxine with 4.4 mg/10 mL of buffer to equal 1.6 mM.
3. Dissolve 125 𝜇𝜇𝜇𝜇 of Venlafaxine into 875 𝜇𝜇𝜇𝜇 of KH2PO4 buffer (that has been already
made) and place in test tube labeled, “Drug Conc. 1”.
4. Dissolve 313 𝜇𝜇𝜇𝜇 of Venlafaxine into 687 𝜇𝜇𝜇𝜇 of KH2PO4 buffer and place into test tube
labeled, “Drug Conc. 2”.
5. Place stock 1000 𝜇𝜇𝜇𝜇 of Venlafaxine into test tube labeled, “Drug Conc. 3”.
6. Dissolve 19 𝜇𝜇𝜇𝜇 of microsomal solution into 125 𝜇𝜇𝜇𝜇 of KH2PO4 buffer and place into test
tube labeled, “Microsomal”
7. Add 200 𝜇𝜇𝜇𝜇 of buffer into the 100 U vial of G6P dehydrogenase. Mix well. Remove 25 𝜇𝜇𝜇𝜇
and add to the NADPH-generating system (step 1). Place the remainder into individual
tubes of 25 𝜇𝜇𝜇𝜇 and freeze, labelled, “12.5 U G6PD 1-7”
8. Take 35 𝜇𝜇𝜇𝜇 of your dissolved NADPH and add to centrifuge tube #1 along with 65 𝜇𝜇𝜇𝜇 of
dissolved Venlafaxine (Drug Conc. 1). Suspend.
9. Take 25 𝜇𝜇𝜇𝜇 of the dissolved microsomal suspension and add it to that centrifuge tube.
Mix again suspend.
10. Take 35 𝜇𝜇𝜇𝜇 of your dissolved NADPH and add to centrifuge tube #2 along with 65 𝜇𝜇𝜇𝜇 of
dissolved Venlafaxine (Drug Conc. 2). Suspend.
11. Take 25 𝜇𝜇𝜇𝜇 of the dissolved microsomal suspension and add it to that centrifuge tube.
Suspend.
12. Take 35 𝜇𝜇𝜇𝜇 of your dissolved NADPH and add to centrifuge tube #3 along with 65 𝜇𝜇𝜇𝜇 of
dissolved Venlafaxine (Drug Conc. 3). Mix on a vortex mixer.
13. Take 25 𝜇𝜇𝜇𝜇 of the dissolved microsomal suspension and add it to that centrifuge tube.
Mix by suspension.
14. Take 35 𝜇𝜇𝜇𝜇 of your dissolved NADPH and add to centrifuge tube #4, labeled, “No drug”
along with 65 𝜇𝜇𝜇𝜇 of KH2PO4 buffer. Suspend.
15. Take 25 𝜇𝜇𝜇𝜇 of the dissolved microsomal suspension and add it to that centrifuge tube.
Mix again by suspending.
16. Repeat the same steps for “Just drug”, “Just drug alone” and “No NADPH”.
17. Incubate all 7 tubes for 2 hours and then add 250 𝜇𝜇𝜇𝜇 of methanol to each tube to stop
the reaction and centrifuge them at 15,000 g x 20 minutes.
18. Extract the supernatants from the tubes and place into 7 new centrifuge tubes. Freeze
until it is time to run in the MS.

19. Extract 10 𝜇𝜇𝜇𝜇 of the supernatant from each tube. Put the 10 𝜇𝜇𝜇𝜇 into 1 mL of MS solution
(that has already been made).
20. Run the MS for all three experiments, follow the videos of Lee.
Protocol for Duloxetine:
1. Create NADPH-generating system by adding 0.492 mg of NADP in 50 𝜇𝜇𝜇𝜇 of buffer to
make 12.5 mM NADP, add 200 𝜇𝜇𝜇𝜇 of buffer into the 100 U vial of G6P dehydrogenase,
and remove 25 𝜇𝜇𝜇𝜇 of the solution to make 12.5 U of G6P dehydrogenase. Create G6P by
adding 0.88 mg of G6P in 100 𝜇𝜇𝜇𝜇 of buffer to make 31.2 mM G6P all together.
Measure out about 0.5 mg of NADP and about 1 mg G6P and add to vial with 160 𝜇𝜇𝜇𝜇 of
buffer. Mix well.
2. Create a stock of Duloxetine with 4.8 mg/10 mL of buffer to equal 1.6 mM.
3. Dissolve 125 𝜇𝜇𝜇𝜇 of Duloxetine into 875 𝜇𝜇𝜇𝜇 of KH2PO4 buffer (that has been already
made) and place in test tube labeled, “Drug Conc. 1”.
4. Dissolve 313 𝜇𝜇𝜇𝜇 of Duloxetine into 687 𝜇𝜇𝜇𝜇 of KH2PO4 buffer and place into test tube
labeled, “Drug Conc. 2”.
5. Place stock 1000 𝜇𝜇𝜇𝜇 of Duloxetine into test tube labeled, “Drug Conc. 3”.
6. Dissolve 19 𝜇𝜇𝜇𝜇 of microsomal solution into 125 𝜇𝜇𝜇𝜇 of KH2PO4 buffer and place into test
tube labeled, “Microsomal”
7. Add 200 𝜇𝜇𝜇𝜇 of buffer into the 100 U vial of G6P dehydrogenase. Mix well. Remove 25 𝜇𝜇𝜇𝜇
and add to the NADPH-generating system (step 1). Place the remainder into individual
tubes of 25 𝜇𝜇𝜇𝜇 and freeze, labelled, “12.5 U G6PD 1-7”
8. Take 35 𝜇𝜇𝜇𝜇 of your dissolved NADPH and add to centrifuge tube #1 along with 65 𝜇𝜇𝜇𝜇 of
dissolved Duloxetine (Drug Conc. 1). Suspend.
9. Take 25 𝜇𝜇𝜇𝜇 of the dissolved microsomal suspension and add it to that centrifuge tube.
Mix again suspend.
10. Take 35 𝜇𝜇𝜇𝜇 of your dissolved NADPH and add to centrifuge tube #2 along with 65 𝜇𝜇𝜇𝜇 of
dissolved Duloxetine (Drug Conc. 2). Suspend.
11. Take 25 𝜇𝜇𝜇𝜇 of the dissolved microsomal suspension and add it to that centrifuge tube.
Suspend.
12. Take 35 𝜇𝜇𝜇𝜇 of your dissolved NADPH and add to centrifuge tube #3 along with 65 𝜇𝜇𝜇𝜇 of
dissolved Duloxetine (Drug Conc. 3). Mix on a vortex mixer.
13. Take 25 𝜇𝜇𝜇𝜇 of the dissolved microsomal suspension and add it to that centrifuge tube.
Mix by suspension.
14. Take 35 𝜇𝜇𝜇𝜇 of your dissolved NADPH and add to centrifuge tube #4, labeled, “No drug”
along with 65 𝜇𝜇𝜇𝜇 of KH2PO4 buffer. Suspend.
15. Take 25 𝜇𝜇𝜇𝜇 of the dissolved microsomal suspension and add it to that centrifuge tube.
Mix again by suspending.
16. Repeat the same steps for “Just drug”, “Just drug alone” and “No NADPH”.
17. Incubate all 7 tubes for 2 hours and then add 250 𝜇𝜇𝜇𝜇 of methanol to each tube to stop
the reaction and centrifuge them at 15,000 g x 20 minutes.
18. Extract the supernatants from the tubes and place into 7 new centrifuge tubes. Freeze
until it is time to run in the MS.

19. Extract 10 𝜇𝜇𝜇𝜇 of the supernatant from each tube. Put the 10 𝜇𝜇𝜇𝜇 into 1 mL of MS solution
(that has already been made).
20. Run the MS for all three experiments, follow the videos of Lee.
Protocol for Escitalopram:
1. Create NADPH-generating system by adding 0.492 mg of NADP in 50 𝜇𝜇𝜇𝜇 of buffer to
make 12.5 mM NADP, add 200 𝜇𝜇𝜇𝜇 of buffer into the 100 U vial of G6P dehydrogenase,
and remove 25 𝜇𝜇𝜇𝜇 of the solution to make 12.5 U of G6P dehydrogenase. Create G6P by
adding 0.88 mg of G6P in 100 𝜇𝜇𝜇𝜇 of buffer to make 31.2 mM G6P all together.
Measure out about 0.5 mg of NADP and about 1 mg G6P and add to vial with 160 𝜇𝜇𝜇𝜇 of
buffer. Mix well.
2. Create a stock of Escitalopram with 5.2 mg/10 mL of buffer to equal 1.6 mM.
3. Dissolve 125 𝜇𝜇𝜇𝜇 of Escitalopram into 875 𝜇𝜇𝐿𝐿 of KH2PO4 buffer (that has been already
made) and place in test tube labeled, “Drug Conc. 1”.
4. Dissolve 313 𝜇𝜇𝜇𝜇 of Escitalopram into 687 𝜇𝜇𝜇𝜇 of KH2PO4 buffer and place into test tube
labeled, “Drug Conc. 2”.
5. Place stock 1000 𝜇𝜇𝜇𝜇 of Escitalopram into test tube labeled, “Drug Conc. 3”.
6. Dissolve 19 𝜇𝜇𝜇𝜇 of microsomal solution into 125 𝜇𝜇𝜇𝜇 of KH2PO4 buffer and place into test
tube labeled, “Microsomal”
7. Add 200 𝜇𝜇𝜇𝜇 of buffer into the 100 U vial of G6P dehydrogenase. Mix well. Remove 25 𝜇𝜇𝜇𝜇
and add to the NADPH-generating system (step 1). Place the remainder into individual
tubes of 25 𝜇𝜇𝜇𝜇 and freeze, labelled, “12.5 U G6PD 1-7”
8. Take 35 𝜇𝜇𝜇𝜇 of your dissolved NADPH and add to centrifuge tube #1 along with 65 𝜇𝜇𝜇𝜇 of
dissolved Duloxetine (Drug Conc. 1). Suspend.
9. Take 25 𝜇𝜇𝜇𝜇 of the dissolved microsomal suspension and add it to that centrifuge tube.
Mix again suspend.
10. Take 35 𝜇𝜇𝜇𝜇 of your dissolved NADPH and add to centrifuge tube #2 along with 65 𝜇𝜇𝜇𝜇 of
dissolved Duloxetine (Drug Conc. 2). Suspend.
11. Take 25 𝜇𝜇𝜇𝜇 of the dissolved microsomal suspension and add it to that centrifuge tube.
Suspend.
12. Take 35 𝜇𝜇𝜇𝜇 of your dissolved NADPH and add to centrifuge tube #3 along with 65 𝜇𝜇𝜇𝜇 of
dissolved Duloxetine (Drug Conc. 3). Mix on a vortex mixer.
13. Take 25 𝜇𝜇𝜇𝜇 of the dissolved microsomal suspension and add it to that centrifuge tube.
Mix by suspension.
14. Take 35 𝜇𝜇𝜇𝜇 of your dissolved NADPH and add to centrifuge tube #4, labeled, “No drug”
along with 65 𝜇𝜇𝜇𝜇 of KH2PO4 buffer. Suspend.
15. Take 25 𝜇𝜇𝜇𝜇 of the dissolved microsomal suspension and add it to that centrifuge tube.
Mix again by suspending.
16. Repeat the same steps for “Just drug”, “Just drug alone” and “No NADPH”.
17. Incubate all 7 tubes for 2 hours and then add 250 𝜇𝜇𝜇𝜇 of methanol to each tube to stop
the reaction and centrifuge them at 15,000 g x 20 minutes.
18. Extract the supernatants from the tubes and place into 7 new centrifuge tubes. Freeze
until it is time to run in the MS.
19. Extract 10 𝜇𝜇𝜇𝜇 of the supernatant from each tube. Put the 10 𝜇𝜇𝜇𝜇 into 1 mL of MS solution
(that has already been made).

20. Run the MS for all three experiments, follow the videos of Lee.
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Results:
Escitalopram

Figure 1: MS Chromatogram of N-Demethylation of Escitalopram
This figure shows three peaks with their retention time and area at the molecular weight of
311.2 with the concentration of 800 𝜇𝜇𝜇𝜇. This is the molecular weight of escitalopram (325)
with a methyl group subtracted from it (-14). Each sample was injected into the mass
spectrometer three times in about a 1.5-minute interval. The demethylated metabolite shows
up at 0.59 min, 2.18 min, and 3.81 min. These peaks were not visible without the presence of
NADPH-generating system, meaning that escitalopram depends on this to metabolize.
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Figure 2: N-Demethylation of Escitalopram
This figure shows the average of all three peaks (Figure 1) plotted against their concentrations:
0, 100, 250 and 800 𝜇𝜇𝜇𝜇. This plot resembles a hyperbolic curve.1-3% of the original
concentration was metabolized.

Figure 3: MS Chromatogram of Aromatic Hydroxylation of Escitalopram
This figure shows three peaks with their retention time and area at the molecular weight of
343.2 with the concentration of 800 𝜇𝜇𝜇𝜇. This is the molecular weight of escitalopram (325)
with a water group added to it (+18). Each sample was injected into the mass spectrometer
three times in about a 1.5-minute interval. The metabolite does not show up at all. The peaks
shown above have retention times that are later than the retention time of the drug at the
molecular weight of 325, indicating that there is no hydroxylated metabolite.
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Figure 4: Aromatic Hydroxylation of Escitalopram
This figure shows the average of all three peaks (Figure 3) plotted against their concentrations:
0, 100, 250 and 800 𝜇𝜇𝜇𝜇. This plot resembles no hydroxylation metabolites.
Venlafaxine

Figure 5: MS Chromatogram of N-Demethylation of Venlafaxine
This figure shows three peaks with their retention time and area at the molecular weight of
264.2 with the concentration of 800 𝜇𝜇𝜇𝜇. This is the molecular weight of venlafaxine (278) with
a methyl group subtracted from it (-14). Each sample was injected into the mass spectrometer
three times every four minutes. The demethylated metabolite shows up at 1.37 min, 5.35 min,
and 9.52 min. There were two peaks developed per round of injections, which means that one
of the peaks was not the demethylated metabolite. Because the metabolite is known to show
up at a retention time before that of the drug’s (1.71 min, 5.69 min and 9.86 min), the first peak
is the actual indication of demethylated metabolites. These peaks were not visible without the
presence of NADPH-generating system. This means that venlafaxine is dependent on this in
order to metabolize.
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Figure 6: N-Demethylation of Venlafaxine
This figure shows the average of all three peaks (Figure 5) plotted against their concentrations:
0, 100, 250 and 800 𝜇𝜇𝜇𝜇. This plot resembles a hyperbolic curve. 0.9-1.5% of the original
concentration was metabolized.

Figure 7: MS Chromatogram of Aromatic Hydroxylation of Venlafaxine
This figure shows three peaks with their retention time and area at the molecular weight of
296.2 with the concentration of 800 𝜇𝜇𝜇𝜇. This is the molecular weight of venlafaxine (278) with
a water group added to it (+18). Each sample was injected into the mass spectrometer three
times every four minutes. The hydroxylated metabolite shows up at 1.14 min, 5.14 min, and
9.29 min.
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Figure 8: Aromatic Hydroxylation of Venlafaxine
This figure shows the average of all three peaks (Figure 7) plotted against their concentrations:
0, 100, 250 and 800 𝜇𝜇𝜇𝜇. This plot resembles no hydroxylation metabolites due to the
inconsistency of the curve. This curve is supposed to be hyperbolic in order to indicate
metabolism.
Duloxetine

Figure 9: MS Chromatogram of N-Demethylation of Duloxetine
This figure shows three peaks with their retention time and area at the molecular weight of
284.2 with the concentration of 800 𝜇𝜇𝜇𝜇. This is the molecular weight of duloxetine (298) with a
methyl group subtracted from it (-14). Each sample was injected into the mass spectrometer
three times every four minutes. The demethylated metabolite shows up at 0.65 min, 4.83 min,
and 8.66 min. These peaks were not visible without the presence of NADPH-generating system,
meaning that duloxetine is not dependent on it to metabolize.
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Figure 10: N-Demethylation of Duloxetine
This figure shows the average of all three peaks (Figure 9) plotted against their concentrations:
0, 100, 250 and 800 𝜇𝜇𝜇𝜇. This plot resembles a hyperbolic curve. 33-72% of the original
concentration was metabolized.

Figure 11: MS Chromatogram of Aromatic Hydroxylation of Duloxetine
This figure shows three peaks with their retention time and area at the molecular weight of
316.2 with the concentration of 800 𝜇𝜇𝜇𝜇. This is the molecular weight of duloxetine (298) with a
water group added to it (+18). Each sample was injected into the mass spectrometer three
times every four minutes. There are no strong peaks that would indicate hydroxylated
metabolites.
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Figure 12: Aromatic Hydroxylation of Duloxetine
This figure shows the average of all three peaks (Figure 11) plotted against their concentrations:
0, 100, 250 and 800 𝜇𝜇𝜇𝜇. This plot resembles no hydroxylation metabolites.
Discussion:
Escitalopram was the first drug that was injected within the compact mass spectrometer,
containing seven samples, three of different concentrations known as 100, 250 and 800 𝜇𝜇𝑀𝑀 and
four controls known as the mixture without the drug, the mixture without NADPH-generating
system, the mixture without the rat liver microsome and just the drug alone. For each sample,
the three peaks at escitalopram’s molecular weight, its weight with fourteen subtracted (Ndemethylation), and its weight with eighteen added (aromatic hydroxylation) were averaged
and used to determine its metabolites. At the molecular weight of 311.2, three strong peaks
with retention times of 0.59 min, 2.18 min, and 3.81 min indicated N-demethylated metabolites
at 800 𝜇𝜇𝜇𝜇. Escitalopram’s N-demethylation metabolized between 1-3%. At the molecular
weight of 343.2, three weak peaks with retention times of 0.76 min, 2.33 min, and 3.96 min
that showed up later than the drug at a molecular weight of 325.2 indicated that there are no
aromatic hydroxylated metabolites at 800 𝜇𝜇𝜇𝜇. Even though there is a slight peak that forms
before each peak that has the right retention times, it is still not thought to be the metabolites
because the peak only appears in the 800 𝜇𝜇𝜇𝜇 concentration and is not a clean peak. In the 100
and 250 𝜇𝜇𝜇𝜇 concentrations, there are no peaks at the molecular weight of 343.2, there is only
noise on each chromatogram. It is unknown what the peak within the 800 𝜇𝜇𝜇𝜇 chromatogram is,
but it could possibly be another component of the sample with the same molecular weight.
Further controls would need to be injected to conclude which constituent contains the same
molecular weight as the possible metabolite. Venlafaxine was the second drug to be injected
and interpreted by averaging the three peaks shown for each of the seven samples. At the
molecular weight of 264.2, two strong peaks per injection displayed. Between the two of them,
the first peak for each injection with retention times of 1.37 min, 5.35 min, and 9.52 min

indicated N-demethylated metabolites at 800 𝜇𝜇𝜇𝜇. The second peak for each injection with
retention times of 2.26 min, 6.23 min, and 10.40 min did not indicate N-demethylated
metabolites due to the drug at the molecular weight of 278.2 having retention times happening
earlier than the second peaks. Metabolites must have retention times earlier than the drug’s to
prove metabolism. Venlafaxine’s N-demethylation metabolized between 0.9-1.5%. At the
molecular weight of 296.2, three peaks with retention times of 1.14 min, 5.14 min, and 9.29
min indicated aromatic hydroxylated metabolites. However, when plotting the average of its
peaks with each concentration injected, the function did not represent a hyperbolic curve. A
hyperbolic curve explains the increase of concentration vs the average area of the peak,
eventually plateauing once it has hit its highest concentration. Because the function did not
represent a hyperbolic curve, it can be assumed that aromatic hydroxylation did not actually
happen within the metabolism of venlafaxine. It is unsure what these peaks are indicating and
further injections with more controls would need to be completed to narrow down what is
happening at this molecular weight. Duloxetine was the last drug to be injected into the
compact mass spectrometer with its seven samples, three times each. At the molecular weight
of 284.2, three strong peaks with the retention times of 0.65 min, 4.83 min, and 8.66 min
indicated N-demethylated metabolites at 800 𝜇𝜇𝜇𝜇. Duloxetine’s N-demethylation metabolized
between 33-72%. At the molecular weight of 316.2, only noise appeared on the chromatogram.
Since no peaks were formed, it is indicated that there was not any aromatic hydroxylation at
800 𝜇𝜇𝜇𝜇. Out of the three drugs, duloxetine metabolized a lot more than escitalopram and
venlafaxine. This is interesting and it is not indicated why. However, when referring to the
structure of duloxetine compared escitalopram and venlafaxine, duloxetine only contains one
methyl group coming off the nitrogen as opposed to two methyl groups coming off of the
nitrogen like the other two drugs. This could be why duloxetine metabolized much more than
the other two, but it is not certain. To further prove this hypothesis, testing of another
antidepressant containing only one methyl group coming off the nitrogen would need to be
metabolized, injected into the compact mass spectrometer and analyzed to see its percentage
of metabolism of N-demethylation. When analyzing the controls for each drug, the control that
contained only the drug and microsome and was lacking the NADPH-generating system gave
interesting results. For escitalopram and venlafaxine, the metabolites did not show up on the
chromatogram in the absence of the NADPH-generating system. However, for duloxetine, the
metabolites of N-demethylation did show up on the chromatogram in the presence of NADPHgenerating system. This concludes that both escitalopram and venlafaxine need NADPHgenerating system when metabolizing and duloxetine does not. While injecting the samples of
escitalopram into the compact mass spectrometer, each sample was injected three times
within 1.5 minute intervals for a total of five minutes. The syringe was changed per sample,
along with a wash of the needle and the column. After analyzing the data, it was then decided
that to see a better separation between the three injections that the intervals needed to be
stretched to every four minutes for a total of twelve minutes. In order to rely on retention
times of the peaks appearing, it was practiced injecting the sample at exactly four minutes
every time. There were a couple of times that samples were injected at a slightly later time,
which could have affected the retention times slightly. Overall, this experiment ran very smooth
and gave useful results.

Conclusion:
According to the results, escitalopram, duloxetine and venlafaxine all underwent Ndemethylation but not aromatic hydroxylation during metabolism in rat liver microsome. Even
though duloxetine was only N-demethylated, it metabolized the most out of all three drugs up
to 30-70%. In conclusion, it was confirmed that escitalopram, venlafaxine and duloxetine
needed rat liver microsomes to metabolize. However, it was also confirmed that only
escitalopram and venlafaxine needed NADPH-generating system as well, to metabolize. In
further studies, repeating these experiments using HPLC/CMS techniques to further separate
the metabolites would be ideal. Although duloxetine metabolized the most, it would be easier
to understand how or why it metabolized the most if we were able to separate the metabolites
further by using these techniques. Using different drugs would also explain the outcome of
metabolism a little further.
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